Neuren Pharmaceuticals (ASX:NEU) was granted a type C Meeting with the US Food and Drug Administration to discuss the primary efficacy endpoints of its phase 3 clinical trial program for a neurodevelopmental disorder drug candidate, the company said in a Friday Australian bourse filing.
The drug candidate, NNZ-2591, is in development for multiple neurodevelopmental disorders and achieved positive results in phase 2 clinical trials in Phelan-McDermid syndrome, Pitt-Hopkins syndrome, and Angelman syndrome, per the filing.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。